News - Refocusing group

March 1st 2007, Accura Pharma the PLUS quoted pharmaceutical company announced today that it will seek to divest its human medicines programmes and focus development on products exclusively for the GBP9 billion animal health market. To help implement this strategy newly appointed Chairman, Kevin Leech, who has extensive experience of partnering projects in the human pharmaceutical industry, will lead the divestment programme.

During the last twelve months Accura has made such significant progress with its lead animal health products that it has become clear the Company needs to focus on these to generate the best return for its shareholders. Accura now has three near to market products, 2 of which are potential blockbusters for the veterinary market. In addition there are a further five candidate products at an earlier stage of development that could be accelerated providing additional resources were devoted to them.

The veterinary pharmaceutical market has been historically underserved. However, over the last twelve months there have been dramatic changes with Pfizer's (NYSE: PFE) entry into the canine obesity market, forecasted to be $2bn and with Lily (NYSE: ELI) announcing in January of 2007 that they were forming an exclusive animal health division to commercialize this growing market. The focus is very much on providing for companion animals the same quality of pharmaceutical products with specific veterinary formulations to satisfy an ever growing demand. The Company is especially excited about this opportunity as there are virtually no stand alone Biotech public companies specializing solely on Animal Healthcare anywhere in the world.

Bernard Ross, CEO of Accura commented "We believe the animal health sector presents such a large short to medium term opportunity that we cannot continue to divert resources away from developing the veterinary formulations for our chosen therapeutic areas and therefore we intend to divest Accura of its early stage human therapeutic division. To achieve the maximum return from our existing investment in
those programmes, Kevin Leech will use his knowledge and expertise to lead the divestment strategy and achieve the best return for Accura and its shareholders".

Newly appointed chairman Kevin Leech commented "I am excited about the possibilities for Accura Pharma as it has such a promising portfolio of products. It has a unique model in that is one of the few stand alone Biotech companies that is
focusing on the Animal Health market place".

The Directors of the issuer accept responsibility for this announcement.